Christopher Freese, MD
Radiation Oncology · Cincinnati, OHNPI 1689084261
Payments from drug & device makers
Across 40 payments — averaging $51.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$1K
- Johnson & Johnson$139
- Merck$70
- Novartis$58
- Amgen$52
- Pharmacyclics LLC, An Abbvie Company$43
- plus $371 from 17 others
What the payments were for
- Consulting fees$1,32564%
- Food & beverage$74136%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 2 | $1,333 |
| Johnson & Johnson(2 entities) | 5 | $139 |
| Merck | 4 | $70 |
| Novartis | 3 | $58 |
| Amgen | 3 | $52 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $43 |
| Adaptive Biotechnologies Corporation | 2 | $39 |
| Puma Biotechnology, Inc. | 2 | $37 |
| Bayer | 2 | $36 |
| Visionrt, Inc. | 1 | $34 |
| Tersera Therapeutics LLC | 2 | $34 |
| Sun Pharmaceutical Industries Inc. | 1 | $22 |
| Bristol Myers Squibb | 1 | $19 |
| Genentech USA, Inc. | 1 | $17 |
| Myovant Sciences Inc. | 1 | $16 |
| Lilly USA, LLC | 1 | $16 |
| Stemline Therapeutics Inc. | 1 | $16 |
| Sanofi | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Sumitomo Pharma America, Inc. | 1 | $14 |
| Siemens Medical Solutions USA, Inc. | 1 | $14 |
| AstraZeneca | 1 | $13 |
| Palette Life Sciences, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LENVIMA$1,325
How this compares
$2,066 in reported general payments places this provider in the 70th percentile of 255 radiation oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 114 | $826 |
| Oxycodone Hcl | 31 | $494 |
| Oxybutynin Chloride ErOxybutynin Chloride | 25 | $442 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 13 | $156 |
| Methylprednisolone | 11 | $61 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Cincinnati
- John BrenemanCincinnati$503K
- Kyle WangCincinnati$412K
- Joseph ShaughnessyCincinnati$242K
- Emily DaughertyCincinnati$213K
- Sara MedekCincinnati$54K
- Bryan RabaticCincinnati$47K
- David LongCincinnati$46K
- Jordan KharofaCincinnati$13K
- Matthew BertkeCincinnati$5K
- Shlomo KoyfmanCleveland$2.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.